"Xinhua Zhu, MD, PhD, is a medical oncologist and hematologist at Monter Cancer Center, where he specializes in treating genitourinary cancer, including cancer of the prostate, kidney, bladder and testicles. He focuses on compassionate, evidence-based care, rooted in his research background.""My research helps me think outside the box when creating treatment plans. Dr. Zhu is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Prostate Cancer, and Chromophobe Renal Cell Carcinoma.

Rohit Jain is an Oncologist and a Hematologist Oncology provider in Flushing, New York. Dr. Jain is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Urothelial Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Penectomy, and Endoscopy. Dr. Jain is currently accepting new patients.

Dr. Simon J Hall MD is a board certified urologist with Fellowship training in Urologic Oncology. His clinical interests include the diagnosis and treatment of Prostate, Bladder and Kidney cancers. He is especially interested in Active Surveillance of men with prostate cancer and men and women with incidentally found small renal masses and the creation of continent urinary reconstructions for patients who need to undergo cystectomy for Bladder cancer. Furthermore, Dr. Hall has a keen interest in treating patients with recurrent prostate cancer following definitive therapy. He believes that objective & balanced communication with the patient and family is the key to decision making and individualized care. Over the years Dr. Hall has been named as Best Doctor, both nationally and regionally, by organizations such as Castle Connolly, SuperDoctors and New York Magazine. Dr. Hall s research has focused of new therapies for prostate and bladder cancer; he has participated in numerous clinical trials, some of which generated data resulting in FDA approval of Sipleucel-T (Provenge) and enzulutamide (Xtandi). He oversees a laboratory investigating novel approaches to negating the Androgen Receptor, an important key driver of castration resistant prostate cancer. Decision making and improved methods of clinical care for patients with bladder and prostate cancer are important aspects of his research interests in collaboration with Dr. Michael Diefenbach, a behavioral scientist in the Departments of Urology & Medicine at NS-LIJ. He has authored or co-authored nearly 70 peer reviewed articles in Journals such as Journal of Urology, Urology, British Journal of Urology, Clinical Cancer Research and Science. Dr. Hall received his MD from the College of Physicians & Surgeons of Columbia University. He then completed two years of Surgery training at the Mount Sinai Medical Center followed by a four year residency in Urology at Boston University School of Medicine. This was followed by a 2 year fellowship in Urologic Oncology in the Scott Department of Urology at Baylor College of Medicine. Prior to joining the Smith Institute for Urology, he served on the faculty of Icahn School of Medicine at Mount Sinai for 18 years, holding various positions including Kyung Hyun Kim MD Chair of Urology and the Director of the Deane Prostate Health & Research Center. Dr. Hall is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Muscle Invasive Bladder Cancer, Prostate Cancer, Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Joph Steckel is an Urologist in Lake Success, New York. Dr. Steckel is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Chromophobe Renal Cell Carcinoma, Nephrectomy, and Reconstructive Urology Surgery.

As Senior Vice President of the Urology Service Line, Chair of theSmith Institute for Urology, and Chair of Urology at the Zucker Schoolof Medicine at Hofstra/Northwell, Samir Taneja, MD will establish hisclinical practice at Lenox Hill Hospital and Long Island Jewish MedicalCenter focused on the surgical management of prostate cancerand renal tumors. He is an expert in urologic oncology, renowned fortransforming the field of prostate cancer diagnosis and treatmentby improving methods of prostate imaging, cancer detection, anddisease localization. Having performed thousands of robotic, ablative,laparoscopic and open surgical procedures, his specific clinical focushas been in improving prostate cancer patient outcomes throughpioneering techniques for focal ablative therapy, refining surgicaltechniques for robotic prostatectomy and partial nephrectomy,devising accelerated recovery pathways for robotic prostatectomy/partial nephrectomy, and providing muti-modal surgical approachesfor patients with high risk and recurrent prostate cancer. As leader ofthe department, he will strive to ensure individualized care of urologicdisease through state-of-the-art surgical approaches and multi-disciplinary care.Prior to joining Northwell, Dr Taneja was a faculty member of NYUGrossman School of Medicine for 29-years as a tenured professorof urology, radiology, and biomedical engineering. Most recently heserved as Director of the Division of Urologic Oncology and ViceChair in the Department of Urology at NYU Langone Health, as well asGenitourinary Program Leader in the Perlmutter Cancer Center.Dr. Taneja has conducted extensive clinical research on the use ofimaging in prostate cancer and is considered a pioneer in the use ofMRI to diagnose and localize prostate cancer and the emerging field ofprostate cancer focal therapy. He has authored more than 250 articles,30 book chapters, and six textbooks and monographs on urologiccancer and surgery. He is the editor of Taneja's Complications ofUrologic Surgery: Prevention and Diagnosis, one of the most widely readtextbooks in American Urology. Dr. Taneja is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Louis Faiella is an Urologist in Mineola, New York. Dr. Faiella is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Boils, and Ureteroscopy.

Alvin Goh is an Urologist in Uniondale, New York. Dr. Goh is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Congenital Giant Megaureter, Cystectomy, and Nephrectomy. Dr. Goh is currently accepting new patients.

Massimiliano Spaliviero is an Urologist in Uniondale, New York. Dr. Spaliviero is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Prostate Cancer, Enlarged Prostate (BPH), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Gary Goldberg is an Urologist in Manhasset, New York. Dr. Goldberg is rated as a Distinguished provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Enlarged Prostate (BPH), Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Ureteroscopy, and Reconstructive Urology Surgery.

John Sfakianos is an Urologist in Long Island City, New York. Dr. Sfakianos is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy.

Reza Mehrazin is an Urologist in Long Island City, New York. Dr. Mehrazin is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Renal Cell Carcinoma (RCC), Nephrectomy, and Cystectomy.

Louis Kavoussi, MD, MBA, Director of teleintervention at Northwell. He is a world-renowned urologic surgeon who brings more than 30 years of specialized expertise in minimally invasive urological surgery. His area of focus includes treating a wide range of urologic diseases, including kidney obstructions, renal stones and urologic cancer. At the forefront of innovation, Dr. Kavoussi pioneered several new surgical techniques, including the first minimally invasive approaches to kidney surgery for kidney cancer and kidney donation. He was also part of the team that performed the first laparoscopic prostate removal for cancer. In 1999, Dr. Kavoussi received a Smithsonian Computerworld Permanent Collection award for his work in developing telerounding, the starting point of telehealth medicine-to facilitate physician communication with hospitalized patients. Before joining Northwell in 2005 as chair of urology, Dr. Kavoussi completed his medical degree at the State University of New York at Buffalo. He obtained his urologic training at Washington University of St. Louis and, directly following residency, was named chief of urology at the Jewish Hospital of St. Louis. In 1991, he was appointed assistant professor at Harvard School of Medicine and director of endourology at the Brigham and Women's Hospital. In 1993, he joined the faculty of Johns Hopkins University School of Medicine, where he was vice chairman of urology and named a Patrick C. Walsh Distinguished Professor. Dr. Kavoussi values a team approach to care, and often collaborates with other specialists to create personalized and comprehensive treatment plans. His patients appreciate his easygoing personality and thoughtfulness. As the Waldbaum-Gardner Distinguished Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Dr. Kavoussi is passionate about training the next generation of surgeons. He has presented his work and given live surgical demonstrations at conferences around the world and has more than 500 academic publications. Dr. Kavoussi is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, Nephrectomy, and Reconstructive Urology Surgery.

Zeph Okeke, MD is a board certified urologic surgeon specializing in endourology, minimally invasive surgery and laparoscopy. He is known for developing and being the principal investigator of the novel S.T.O.N.E. classification system for kidney stones.His expertise is in using minimally invasive techniques for the management of complex kidney and ureteral stone disease, and urothelial cancers (transitional cell carcinoma) of the kidney and ureter. He also has special interest and expertise in Holmium and Thulium laser enucleation (HOLEP and ThuLEP) for enlarged prostates (BPH).In addition to treating patients and conducting research, Dr. Okeke serves as co-director of the Smith Institute for Urology endourology and laparoscopy fellowship training programs. He lectures at the American Urological Association s annual meetings and is frequently invited to speak before the World Congress of Endourology. A mentor and teacher, Dr. Okeke also serves as a surgeon and lecturer for live surgical demonstration courses at various international meetings.Dr. Okeke earned his medical degree from Cornell University Medical College in New York City. He completed his Urology residency and served as Chief Resident in the Department of Urology at the New York Presbyterian Hospital-Columbia University College of Physicians & Surgeons.Dr. Okeke's research interest includes surgical outcomes of kidney stone patients, grading and characterizing complex kidney stones to guide surgery and counseling with respect to outcomes. He has published in leading journals and textbooks including the Smith's Textbook of Endourology, Journal of Urology, Urology and Cancer.He is the recipient of the Teacher of the Year Award at the North Shore LIJ Health System. Dr. Okeke also received the prestigious Arnold P. Gold Foundation Teaching Award for Humanism and Excellence in Teaching. Columbia University College of Physicians & Surgeons awarded its first Lifetime Achievement Award to Dr. Okeke for medical student teaching during his residency. Dr. Okeke is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Kidney Stones, Horseshoe Kidney, Bladder Stones, Ureteroscopy, and Endoscopy.

David Chan is an Urologist in Lake Success, New York. Dr. Chan is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Enlarged Prostate (BPH), Obstructive Uropathy, Boils, Ureteroscopy, and Prostatectomy.

Toby Handler is an Urologist in Mineola, New York. Dr. Handler is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. Her top areas of expertise are Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Urinary Incontinence, Stress Urinary Incontinence, and Ureteroscopy.

Joseph Jamal is an Urologist in Garden City, New York. Dr. Jamal is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Ureterocele, Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Nephrectomy, and Reconstructive Urology Surgery.

Daniel Rittenberg is an Urologist in Garden City, New York. Dr. Rittenberg is rated as an Advanced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Obstructive Uropathy, Urinary Tract Infection in Children, Urinary Tract Infection (UTI), Ureteroscopy, and Reconstructive Urology Surgery.

Robert Moldwin, MD, FACS is Director of the Pelvic Pain Center at The Arthur Smith Institute for Urology and serves as physician-in-charge of Urologic Infectious/Inflammatory Diseases. He is Professor of Urology at the Hofstra North Shore-LIJ School of Medicine.A world-renowned leader in the field of pelvic pain, Dr. Moldwin has special interests in varied pain syndromes of the bladder and pelvis. His other clinical and research interests range from urinary incontinence to infectious diseases of the urinary tract. Dr. Moldwin is published in peer-reviewed journals including Cancer, The Journal of Urology, The British Journal of Urology International, The British Medical Journal, Contemporary Urology and Urology. Dr. Moldwin is an expert consultant, lecturing to audiences of physicians, patients, and members of the media on issues such as incontinence, urological health, interstitial cystitis, and pelvic disorders. He currently serves on multiple medical advisory boards, including the Interstitial Cystitis Association, and has been a member of their Board of Directors for over a decade.Dr Moldwin is affiliated with numerous medical societies including the American Urological Association, International Association for the Study of Pain and The Society for Female Urology and Urodynamics. He is past president of the Society for Infections and Inflammation in Urology. He was also co-chairperson for the recently completed Multidisciplinary Approaches to the Study of Chronic Urologic Pelvic Pain (MAPP), a research initiative sponsored by the National Institutes of Health. Dr Moldwin is currently a committee reviewer for the American Urological Association IC/BPS Guidelines and serves as Vice-President for the International Society for the Study of Interstitial Cystitis/Bladder Pain Syndrome (ESSIC).After earning his medical degree at the University of Chicago Pritzker School of Medicine, Dr. Moldwin completed his general surgical training and urology residency at the Long Island Jewish Medical Center. He also served as a Valentine Fellow through the New York Academy of Medicine, studying infectious and inflammatory urological diseases in the Department of Urology at Thomas Jefferson Medical College in Philadelphia. Dr. Moldwin is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Interstitial Cystitis, Frequent or Urgent Urination, Bacterial Prostatitis, and Vulvodynia.

Dr. Rofeim joined the medical staff of the Smith Institute for Urology and the Hofstra NS-LIJ School of Medicine in July 2012 after being in private practice in the New York area for 10 years. After completion of general surgery training at LIJ and Beth Israel Medical Centers, he continued with urology residency at LIJ Medical Center where he served as the chief resident under the mentorship of Drs. Arthur Smith and Gopal Badlani. He graduated magna cum laude from CUNY-Queens College and cum laude from SUNY-Downstate Medical Center.During his undergraduate training, he won numerous awards including the Donald E. Lancefield Prize, the Howard Hughes Summer Fellowship Award for undergraduate research, the Robert Keating Memorial Award and was included in the National Dean's List. He received the prestigious American Medical Association Physician Recognition Award and AUA/Praecis Gerald P. Murphy Scholar Award for Distinction in the study of prostate cancer. During his residency training, he won the Academic Annual Research Competition at LIJ Medical Center.He is a member of the Alpha Omega Alpha Medical Honor Society where he served as the vice president, the American Urologic Society and the New York Section of the American Urologic Society. Dr. Rofeim is a diplomate of the American Board of Urology (Board certified) and a fellow of the American College of Surgeons. He has published several articles and a book chapter in the fileds of fertility and incontinence and has presented numerous abstracts at the American Urologic Association annual meetings and other prestigious societies in topics of fertility and interstitial cystitis. Interests include:Enlarged ProstateErectile DysfunctionGeneral UrologyIncontinenceKidney StonesUrologic Cancers. Dr. Rofeim is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Diphallia, Enlarged Prostate (BPH), and Ureteroscopy.

Gideon Richards is an Urologist in Garden City, New York. Dr. Richards is rated as an Experienced provider by MediFind in the treatment of Urothelial Cancer. His top areas of expertise are Bilateral Hydronephrosis, Hydronephrosis, Obstructive Uropathy, Ureteroscopy, and Nephrectomy.